Rami Yoseph

This inventor holds 6 USPTO granted patents and 9 published patent applications and 1 EPO patent. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2022-2026.

USPTO Granted Patents = 6 (Patent Applications = 9)

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 11)

Average Co-Inventor Count = 4.3

ph-index = 1

Location History:

Rockville, MD (US) (2022)
Gaithersburg, MD (US) (2022 - 2024)

Company Filing History:

6 out of 3,688

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

Years Active: 2022-2026

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12655195 - HLA CLASS II-RESTRICTED DQ T CELL RECEPTORS AGAINST RAS WITH G13D MUTATION (2026-06-16),

2. 12655193 - HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION (2026-06-16),

3. 12448428 - HLA class II-restricted t cell receptors against RAS with G12R mutation (2025-10-21),

4. 11939365 - T cell receptors recognizing mutated P53 (2024-03-26),

5. 11466071 - HLA class I-restricted t cell receptors against mutated RAS (2022-10-11),

6. 11306132 - HLA class II-restricted T cell receptors against mutated RAS (2022-04-19),

Title: Rami Yoseph: Innovator in Cancer Immunotherapy

Introduction

Rami Yoseph is a prominent inventor based in Rockville, MD, who has made significant contributions to the field of cancer immunotherapy. With a total of four patents to his name, he is recognized for his innovative approaches to targeting cancer cells through T cell receptors.

Latest Patents

Yoseph's latest patents include groundbreaking work on HLA class II-restricted T cell receptors against RAS with the G12R mutation. This patent discloses an isolated or purified T cell receptor (TCR) that has antigenic specificity for a mutated human RAS amino acid sequence, specifically where glycine at position 12 is substituted with arginine. The patent also covers related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions. Additionally, it outlines methods for detecting cancer in mammals and strategies for treating or preventing cancer. Another significant patent involves T cell receptors recognizing mutated P53, which similarly provides a TCR with specificity for mutated human p53, along with related components and methods for cancer detection and treatment.

Career Highlights

Rami Yoseph is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this esteemed institution has allowed him to focus on innovative cancer therapies that harness the body's immune system to combat malignancies.

Collaborations

Yoseph has collaborated with notable colleagues in the field, including Steven A. Rosenberg and Anna Pasetto. These partnerships have further enhanced his research and development efforts in cancer immunotherapy.

Conclusion

Rami Yoseph's contributions to cancer immunotherapy through his patents and research at the National Institutes of Health highlight his role as a leading innovator in the field. His work continues to pave the way for new therapeutic strategies in the fight against cancer.